Theodore Alan Huizenga Sells 1,283 Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock

by · The Markets Daily

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Free Report) CAO Theodore Huizenga sold 1,283 shares of the firm’s stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $13.57, for a total value of $17,410.31. Following the transaction, the chief accounting officer directly owned 67,863 shares in the company, valued at approximately $920,900.91. This represents a 1.86% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Theodore Alan Huizenga also recently made the following trade(s):

  • On Thursday, September 3rd, Theodore Huizenga sold 161 shares of Ultragenyx Pharmaceutical stock. The shares were sold at an average price of $13.99, for a total value of $2,252.39.

Ultragenyx Pharmaceutical Trading Down 1.5%

Ultragenyx Pharmaceutical stock opened at $12.88 on Thursday. The stock has a 50 day moving average of $24.67 and a two-hundred day moving average of $24.55. Ultragenyx Pharmaceutical Inc. has a twelve month low of $12.73 and a twelve month high of $39.89. The stock has a market capitalization of $1.27 billion, a price-to-earnings ratio of -2.21 and a beta of 0.31.

Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) last released its earnings results on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.22) by $0.32. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 81.79%.The business had revenue of $214.00 million for the quarter, compared to analyst estimates of $183.08 million. During the same quarter in the previous year, the company posted ($1.17) earnings per share. The company’s revenue for the quarter was up 28.5% compared to the same quarter last year. Equities analysts predict that Ultragenyx Pharmaceutical Inc. will post -3.98 earnings per share for the current year.

Institutional Trading of Ultragenyx Pharmaceutical

Several hedge funds and other institutional investors have recently made changes to their positions in RARE. BlackRock Inc. acquired a new stake in Ultragenyx Pharmaceutical in the second quarter valued at $355,746,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Ultragenyx Pharmaceutical during the 2nd quarter worth $6,397,000. Deutsche Bank AG purchased a new stake in shares of Ultragenyx Pharmaceutical in the 2nd quarter worth about $5,503,000. Corient Private Wealth LP purchased a new stake in shares of Ultragenyx Pharmaceutical in the 2nd quarter worth about $4,644,000. Finally, Blue Owl Capital Holdings LP acquired a new stake in Ultragenyx Pharmaceutical in the 2nd quarter valued at about $6,098,000. Institutional investors and hedge funds own 97.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on RARE shares. Royal Bank Of Canada cut shares of Ultragenyx Pharmaceutical from a “moderate buy” rating to a “hold” rating in a research note on Thursday, September 3rd. Wells Fargo & Company downgraded shares of Ultragenyx Pharmaceutical from an “overweight” rating to an “equal weight” rating and reduced their price objective for the company from $50.00 to $18.00 in a research report on Thursday, September 3rd. Wedbush lowered their price objective on Ultragenyx Pharmaceutical from $30.00 to $23.00 and set a “neutral” rating on the stock in a report on Thursday, September 3rd. Cantor Fitzgerald dropped their target price on Ultragenyx Pharmaceutical from $103.00 to $33.00 and set an “overweight” rating on the stock in a research report on Thursday, September 3rd. Finally, Robert W. Baird downgraded Ultragenyx Pharmaceutical from an “outperform” rating to a “neutral” rating and cut their target price for the stock from $40.00 to $16.00 in a research note on Thursday, September 3rd. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $36.63.

Check Out Our Latest Analysis on RARE

About Ultragenyx Pharmaceutical

(Get Free Report)

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare diseases. The company’s work includes therapies for genetic, metabolic and skeletal disorders, with an emphasis on conditions that have limited or no effective treatment options.

Ultragenyx’s marketed products include Crysvita (burosumab), used to treat certain forms of X-linked hypophosphatemia and tumor-induced osteomalacia; Dojolvi (triheptanoin), a medical food for long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab), a treatment for homozygous familial hypercholesterolemia.

See Also